Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519443 | 0.87 | HCRTR1 (0.60) | HCRTR2HCRTR1 | |
| SCHEMBL15520018 | 0.80 | HCRTR1 (0.58) | HCRTR2HCRTR1 | |
| SCHEMBL15520281 | 0.76 | HCRTR2 (0.53) | HCRTR2HCRTR1 | |
| SCHEMBL15519928 | 0.74 | HCRTR1 (0.47) | HCRTR2HCRTR1 | |
| SCHEMBL15519822 | 0.72 | TNKS (0.46) | HCRTR2HCRTR1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15519901 | 0.72 | HCRTR1 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL15519621 | 0.71 | HCRTR1 (0.43) | HCRTR2HCRTR1POLBSMN1; SMN2NPC1 | |
| SCHEMBL16648633 | 0.71 | HCRTR1 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL15519358 | 0.71 | HCRTR1 (0.60) | HCRTR2HCRTR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15519808 | 0.70 | HCRTR1 (0.62) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20090036357-A1 | Azapeptide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036357-A1 | Azapeptide derivatives | SAMHD1, ENTPD5, DNPEP | HCRTR2 4556/4885HCRTR1 4505/4885POLB 1449/4885 |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | HCRTR2 1/4885HCRTR1 2/4885POLB 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.